JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES

Abstract

Revefenacin, a long-acting muscarinic receptor antagonist was approved by US Food and Drug Administration in November 2018 for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). It is administered by inhalational route once-daily. Most common adverse reactions observed during the clinical trials were cough, nasopharyngitis, upper respiratory tract infection, headache, and back pain. To be avoided in patients with hepatic impairment and history of hypersensitivity reaction to revefenacin.

Key-words: Revefenacin, Chronic Obstructive Pulmonary Disease, Muscarinic receptor antagonist